[go: up one dir, main page]

CY1114737T1 - Παραγωγα κινοξαλινδιονης - Google Patents

Παραγωγα κινοξαλινδιονης

Info

Publication number
CY1114737T1
CY1114737T1 CY20131101166T CY131101166T CY1114737T1 CY 1114737 T1 CY1114737 T1 CY 1114737T1 CY 20131101166 T CY20131101166 T CY 20131101166T CY 131101166 T CY131101166 T CY 131101166T CY 1114737 T1 CY1114737 T1 CY 1114737T1
Authority
CY
Cyprus
Prior art keywords
kinoxalindion
products
obesity
diabetes
inflammation
Prior art date
Application number
CY20131101166T
Other languages
English (en)
Inventor
Daniel Cravo
Sophie Hallakou-Bozec
Franck Lepifre
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CY1114737T1 publication Critical patent/CY1114737T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ενώσεις του χημικού τύπου (Ι) όπου τα Χ, Υ, Ζ, R1, R2, R3 καθορίζονται ως στην αξίωση 1, συμπεριλαμβάνοντας φαρμακευτικές συνθέσεις εξ αυτών και για τη χρήση αυτών στην αγωγή και/ή πρόληψη του διαβήτη, του μεταβολικού συνδρόμου, της παχυσαρκίας, του καρκίνου, της φλεγμονής.
CY20131101166T 2008-06-16 2013-12-27 Παραγωγα κινοξαλινδιονης CY1114737T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290564 2008-06-16
EP09765489.1A EP2285786B1 (en) 2008-06-16 2009-05-19 Quinoxalinedione derivatives

Publications (1)

Publication Number Publication Date
CY1114737T1 true CY1114737T1 (el) 2016-12-14

Family

ID=40823394

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131101166T CY1114737T1 (el) 2008-06-16 2013-12-27 Παραγωγα κινοξαλινδιονης

Country Status (25)

Country Link
US (2) US8329698B2 (el)
EP (1) EP2285786B1 (el)
JP (1) JP5596676B2 (el)
KR (1) KR101641391B1 (el)
CN (1) CN102066342B (el)
AR (1) AR072148A1 (el)
AU (1) AU2009259754B2 (el)
BR (1) BRPI0915064B8 (el)
CA (1) CA2728018C (el)
CO (1) CO6321252A2 (el)
CY (1) CY1114737T1 (el)
DK (1) DK2285786T3 (el)
EA (1) EA020236B1 (el)
EC (1) ECSP11010760A (el)
ES (1) ES2436195T3 (el)
HK (1) HK1157784A1 (el)
HR (1) HRP20131069T1 (el)
IL (1) IL209421A (el)
MX (1) MX2010013577A (el)
MY (1) MY155695A (el)
NZ (1) NZ590503A (el)
PL (1) PL2285786T3 (el)
PT (1) PT2285786E (el)
SI (1) SI2285786T1 (el)
WO (1) WO2009152909A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
IN2014KN02601A (el) 2012-04-24 2015-05-08 Vertex Pharma
PT2970218T (pt) 2013-03-12 2019-03-01 Vertex Pharma Inibidores de adn-pk
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
ES2802296T3 (es) 2013-10-17 2021-01-18 Vertex Pharma Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
JP2019529475A (ja) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法
WO2020190939A1 (en) * 2019-03-18 2020-09-24 University Of Washington Methods of promoting cellular maturation with ampk activators
CN110642798B (zh) * 2019-11-10 2020-07-24 湖南科技学院 一种n-取代-1,4-二氢-2,3-喹喔啉二酮化合物的绿色合成方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
JP2023544026A (ja) 2020-09-30 2023-10-19 バイオベラティブ セラピューティクス インコーポレイテッド Ａｍｐｋ活性化因子及びその使用方法
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
WO2022114812A1 (ko) * 2020-11-26 2022-06-02 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
EP0963372A1 (en) 1997-02-18 1999-12-15 American Home Products Corporation 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists
CA2445650A1 (en) * 2001-05-25 2002-12-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
KR20060130159A (ko) * 2004-01-06 2006-12-18 얀센 파마슈티카 엔.브이. 당뇨병 및 비만증 치료용 글리코겐 인산화효소억제제로서의(3-옥소-3,4-디하이드로-퀴녹살린-2-일-아미노)-벤즈아미드유도체 및 관련 화합물
MY139645A (en) * 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
WO2007136465A2 (en) * 2006-05-15 2007-11-29 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
FR2903695B1 (fr) * 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
PT2285786E (pt) 2014-01-07
IL209421A0 (en) 2011-01-31
BRPI0915064B8 (pt) 2021-05-25
CN102066342B (zh) 2013-09-04
CO6321252A2 (es) 2011-09-20
CN102066342A (zh) 2011-05-18
AR072148A1 (es) 2010-08-11
EP2285786B1 (en) 2013-10-09
ECSP11010760A (es) 2011-02-28
US20120322806A1 (en) 2012-12-20
US20110130404A1 (en) 2011-06-02
US8329698B2 (en) 2012-12-11
EA201100007A1 (ru) 2011-08-30
AU2009259754A1 (en) 2009-12-23
KR20110017455A (ko) 2011-02-21
HRP20131069T1 (hr) 2013-12-20
US8674097B2 (en) 2014-03-18
BRPI0915064B1 (pt) 2019-10-08
PL2285786T3 (pl) 2014-01-31
BRPI0915064A2 (pt) 2015-10-27
WO2009152909A1 (en) 2009-12-23
AU2009259754B2 (en) 2014-10-02
EP2285786A1 (en) 2011-02-23
MY155695A (en) 2015-11-13
KR101641391B1 (ko) 2016-07-20
CA2728018C (en) 2016-10-11
ES2436195T3 (es) 2013-12-27
DK2285786T3 (da) 2013-11-04
EA020236B1 (ru) 2014-09-30
SI2285786T1 (sl) 2014-02-28
HK1157784A1 (en) 2012-07-06
JP2011524384A (ja) 2011-09-01
MX2010013577A (es) 2010-12-21
JP5596676B2 (ja) 2014-09-24
NZ590503A (en) 2012-08-31
CA2728018A1 (en) 2009-12-23
IL209421A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
CY1114737T1 (el) Παραγωγα κινοξαλινδιονης
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
UA107783C2 (en) Isoindoline compounds for use in treating cancer
CY1119714T1 (el) Ενωσεις αναστολεων
CY1117580T1 (el) Νεα ετεροκυκλικα παραγωγα και η χρηση τους στη θεραπεια νευρολογικων διαταραχων
CY1119730T1 (el) Παραγωγα καρβοξυλικου οξεος πυρρολιδινης ως αγωνιστες του συζευγμενου με πρωτεϊνή-g υποδοχεα 43 (gpr43), φαρμακευτικη συνθεση και μεθοδοι για χρηση στην αντιμετωπιση μεταβολικων διαταραχων
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
CY1118658T1 (el) Συνθεση 18f-ραδιοεπισημασμενων στυρυλοπυριδινων απο τοσυλικες προδρομες ενωσεις και σταθερες φαρμακευτικες συνθεσεις αυτων
CY1117330T1 (el) Βενζοδιοξινυλ υποκατεστημενα παραγωγα ινδαζολιου
CY1113269T1 (el) Παραγωγα ινδαζολυλ αμιδιου για τη θεραπευτικη αγωγη διαταραχων διαμεσολαβουμενων υπο υποδοχεα γλυκοκορτικοειδων
MA32811B1 (fr) Nouveaux composés
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
CY1116034T1 (el) 2-ανιλινοβενζιμιδαζολο-6-καρβοξαμιδια ως αντι-φλεγμονωδεις παραγοντες
BRPI0908637B8 (pt) composto e composição farmacêutica do mesmo
CY1111454T1 (el) Παραγωγα φαινυλο-πυραζολιου ως συνδετες υποδοχεα μη στεροειδων γλυκοκορτικοειδων
EA201170772A1 (ru) Органические соединения
NI201300074A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos.
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2014012695A (es) Derivados de isoindolona.
CY1110419T1 (el) Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ
CY1115590T1 (el) Σουλφοξιμινυποκατεστημενα παραγωγα ανιλινοπυριμιδινης ως cdk-αναστολεις, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MA32505B1 (fr) 5-alcynyl-pyrimidines